21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

§ 211.94 Drug product containers and closures

Subpart E - Control of Components and Drug Product Containers and Closures Official text on eCFR Amendment history

(a) Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirements.

(b) Container closure systems shall provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

(c) Drug product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use. Such depyrogenation processes shall be validated.

(d) Standards or specifications, methods of testing, and, where indicated, methods of cleaning, sterilizing, and processing to remove pyrogenic properties shall be written and followed for drug product containers and closures.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 211.94

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Drugs).

  • Containers & Closures Clean, Sterilized, Pyrogen-free 44
  • Protection from external factors 35
  • Reactive/Additive/Absorptive Containers/Closures 17
  • Written Procedures to Remove Pyrogens 4

Warning letters citing § 211.94

10 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 211.94

Amendment history

Federal Register documents that created or amended this section.